Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Del Williams
Options to address the risk of combustible dust explosions for NFPA 61 compliance
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind
Dirk Dusharme @ Quality Digest
Companies say they plan to pull some or all of their devices
Dirk Dusharme @ Quality Digest
First step, migrate your QMS to a cloud-based electronic quality management system

More Features

FDA Compliance News
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth

More News

Quality Digest

FDA Compliance

Pharmaceutical Companies Preparing for Avian Flu Outbreak

Published: Wednesday, October 26, 2005 - 21:00

The Pharmaceutical Research and Manufacturers of America reports that PhRMA member-companies are helping world governments prepare for the possibility of an avian flu pandemic.An important line of defense in the event of an outbreak will be antiviral drugs such as Tamiflu, a Roche product, and Relenza, a GlaxoSmithKline product. Roche and GSK are working with the World Health Organization to establish rapid-response stockpiles to slow or halt an influenza pandemic, and Roche has received and will fill stockpile orders from around 40 nations. The U.S. government currently has enough Tamiflu for 2.3 million Americans.

GSK is expanding its Relenza manufacturing capabilities and has contracted with several countries, including the United States, to provide antiviral treatments. The company is also working to develop an avian flu vaccine, and has clinical trials with the H5N1 strain planned for 2006.

“These treatments and vaccines are important to address the possible public health concerns arising from an avian flu outbreak,” says Billy Tauzin, president and CEO of the PhRMA. “PhRMA member-companies also are working with U.S. and foreign governments to monitor bird-flu developments, an important step in addressing the health threat. We will continue to be vigilant and responsive to the needs of governments and the public as we work to avoid the spread of avian influenza.”

For more information, visit www.phrma.org.

Discuss

About The Author

Quality Digest’s picture

Quality Digest

For 40 years Quality Digest has been the go-to source for all things quality. Our newsletter, Quality Digest, shares expert commentary and relevant industry resources to assist our readers in their quest for continuous improvement. Our website includes every column and article from the newsletter since May 2009 as well as back issues of Quality Digest magazine to August 1995. We are committed to promoting a view wherein quality is not a niche, but an integral part of every phase of manufacturing and services.